Vyriad and Merck launch Phase 1 trial for innovative immuno-oncology drug combination

Vyriad, a US-based biotech company, has partnered with Germany's Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the ... Read More